These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38888762)

  • 1. Zevorcabtagene Autoleucel: First Approval.
    Dhillon S
    Mol Diagn Ther; 2024 Jul; 28(4):501-506. PubMed ID: 38888762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma.
    Rujirachaivej P; Siriboonpiputtana T; Luangwattananun P; Yuti P; Wutti-In Y; Choomee K; Sujjitjoon J; Chareonsirisuthigul T; Rerkamnuaychoke B; Junking M; Yenchitsomanus PT
    Clin Exp Med; 2024 Apr; 24(1):90. PubMed ID: 38683232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma.
    Guo J; Wu Q; Li H; Liang C; Dai J; Zhang S; Dai C; Zhang J; Wen Y; Yang W
    Front Immunol; 2024; 15():1435934. PubMed ID: 39606226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma.
    Wang T; Yang Y; Ma L; Feng R; Li J; Zhang C; Bai J; Ding Y; Liu G; Wu F; Lu X; Feng S; Li Z; He T; Li J; Liu H
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39313307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.
    Xu J; Wang BY; Yu SH; Chen SJ; Yang SS; Liu R; Chen LJ; Hou J; Chen Z; Zhao WH; He AL; Mi JQ; Chen SJ
    J Hematol Oncol; 2024 Apr; 17(1):23. PubMed ID: 38659046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical analysis of the correlation between the expression of soluble B cell maturation antigen and the efficacy of chimeric antigen receptor T cell targeting B cell maturation antigen in patients with multiple myeloma].
    Gao SQ; Mu J; Li X; Wang J; Cui R; Li JY; Sui T; Deng Q
    Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):378-382. PubMed ID: 38951066
    [No Abstract]   [Full Text] [Related]  

  • 7. BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma.
    Yan Y; Tu Y; Cheng Q; Zhang J; Wang E; Deng Z; Yu Y; Wang L; Liu R; Chu L; Kang L; Liu J; Li X
    J Transl Med; 2024 Nov; 22(1):1087. PubMed ID: 39614361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.
    Reece D; Imrie K; Stevens A; Smith CA;
    Curr Oncol; 2006 Oct; 13(5):160-72. PubMed ID: 22792013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Construction of CD138-targeted chimeric antigen receptor- modified T cells and their effect in multiple myeloma therapy].
    Guo CC; Lu Y; Tang KJ; Xing HY; Tian Z; Rao Q; Wang M; Xiong DS; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):436-444. PubMed ID: 38964917
    [No Abstract]   [Full Text] [Related]  

  • 10. Talicabtagene Autoleucel: First Approval.
    Nie T
    Mol Diagn Ther; 2024 Jul; 28(4):495-499. PubMed ID: 38780683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target antigen.
    Esquinas E; Moreno-Sanz A; Sandá V; Stodulski-Ciesla D; Borregón J; Peña-Blanque V; Fernández-Calles J; Fernandez-Fuentes N; Serrano-Lopez J; Juan M; Engel P; Llamas-Sillero P; Solán-Blanco L; Martin-Antonio B
    J Immunother Cancer; 2024 Dec; 12(12):. PubMed ID: 39694704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are we there yet? CAR-T therapy in multiple myeloma.
    Mirvis E; Benjamin R
    Br J Haematol; 2024 Dec; 205(6):2175-2189. PubMed ID: 39558776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies.
    Touzeau C; Krishnan AY; Moreau P; Perrot A; Usmani SZ; Manier S; Cavo M; Martinez Chamorro C; Nooka AK; Martin TG; Karlin L; Leleu X; Bahlis NJ; Besemer B; Pei L; Stein S; Wang Lin SX; Trancucci D; Verona RI; Girgis S; Miao X; Uhlar CM; Chastain K; Garfall AL
    Blood; 2024 Dec; 144(23):2375-2388. PubMed ID: 39172760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma.
    Lee H; Durante M; Skerget S; Vishwamitra D; Benaoudia S; Ahn S; Poorebrahim M; Barakat E; Jung D; Leblay N; Ziccheddu B; Diamond B; Papadimitriou M; Cohen AD; Landgren O; Neri P; Maura F; Bahlis NJ
    Blood; 2024 Dec; 144(25):2637-2651. PubMed ID: 39321344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced cytotoxicity in multiple myeloma via T cells armed with bispecific T cell engager targeting B-cell maturation antigen on cancer cells and CD3 on T cells.
    Supimon K; Sangsuwannukul T; Luangwattananun P; Yenchitsomanus PT
    Int Immunopharmacol; 2024 Dec; 143(Pt 2):113480. PubMed ID: 39467352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [BCMA chimeric antigen receptor T cells therapy re-treatment of a patient with recurrent/refractory IgD multiple myeloma: A case report and literature review].
    Gu SN; Qiang WT; Lu J; Feng ZY; Du J
    Zhonghua Xue Ye Xue Za Zhi; 2024 Oct; 45(10):951-955. PubMed ID: 39622760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report.
    Yan W; Xiong Y; Lv R; Du C; Yu T; Zhang S; Sui W; Deng S; Xiao J; Xu Y; Zou D; Qiu L; An G
    J Immunother Cancer; 2024 Nov; 12(11):. PubMed ID: 39608976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes with chimeric antigen receptor T-cell therapy in Rheumatological disorders: A systematic review.
    Zulfiqar F; Shahzad M; Amin MK; Vyas A; Sarfraz Z; Zainab A; Qasim H; Kaur D; Khavandgar N; Lutfi F; Hematti P; McGuirk JP; Mushtaq MU
    Transpl Immunol; 2024 Dec; 87():102137. PubMed ID: 39442586
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.